Periodicidad semestral: flujo continuo.
ISSN - Electrónico: 2661-6947 / DOI: 10.36015 • LILACS BIREME (19784); LATINDEX (20666)
Introduction: febrile neutropenia is one of the most common and fatal complications of hematologic malignancies treatment. Immediate treatment with broad-spectrum antibiotic is necessary; however the causal agent cannot be isolated in most cases. The use of infection biomarkers such as procalcitonin has proven useful in predicting bacteremia in febrile neutropenic patients receiving chemotherapy. Materials and methods: two peripheral blood samples were aken for blood culture and 3 cc for procalcitonin determination of patients with temperature and leucocyte count below 500, having received chemotherapy for hematological neoplasia. Results: 106 febrile episodes in 66 patients were studied obtaining 84% sensitivity, 55.1% specifcity, PPV 29%, 94% VPN procalcitonin for diagnosis of bacteremia compared to the Gold Standard blood culture. Conclusions: procalcinotin is a useful test to predict bacteremia and high risk septic shock in febrile neutropenic patients.
Naurois, J. Management of febrile neutropenia: ESMO Clinical Practice Guidelines, Annals of Oncology, 2010 (Supplement 5): v252–v256
Derek, C et. al., Severe Sepsis and Septic Shock N Engl J Med, 2013;369:840-51
Maruna, P. Physiology and genetics of procalcitonin. Physiolo Res 49, 2000; (supp. 1) s57-s61
Schuetz, P. Procalcitonin for diagnosis of infection and guide to antibiotic decisions: past, present and future. BMC Medicine, 2011;9:107
Agarwal, R. Procalcitonin to Guide Duration of Antimicrobial Therapy in Intensive Care Units: A Systematic Review. Clinical Infectious Diseases, 2011;53(4):379–387
Freifeld, A. Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases 2011;52(4):e56–e93
Mohsen, M. Procalcitonin and quantitative C-reactive protein role in the early diagnosis of sepsis in patients with febrile neutropenia. South Asian Journal of Cancer 2013; Volume 2 Issue 4
Massaro, K. Procalcitonin (PCT) and C-reactive Protein (CRP) as severe systemic infection markers in febrile neutropenic adults. BMC Infectious Diseases 2007, 7:137
Evangelos, J. Assessment of Procalcitonin as a Diagnostic Marker of Underlying Infection in Patients with Febrile Neutropenia. CID
:32
Kibe, S. Diagnostic and prognostic biomarkers of sepsis in critical care. J Antimicrob Chemother 2011;66 Suppl 2: ii33 – ii40
Wacker, C. Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis. Lancet Infect Dis 2013; 13: 426–35
Simon, L. Serum Procalcitonin and C-Reactive Protein Levels as Markers of Bacterial Infection: A Systematic Review and Meta- analysis. Clinical Infectious Diseases 2004; 39:206–17
Phillips, R. Systematic review and meta-analysis of the value of initial biomarkers in predicting adverse outcome in febrile neutropenic episodes in children and young people with cancer. BMC Medicine 2012; 10:6
Yong, Kim D. The Usefulness of Procalcitonin and C-Reactive Proteinas Early Diagnostic Markers of Bacteremia in Cancer Patients with Febrile Neutropenia. Cancer Res Treat. 2011;43(3):176-180
The authors who publish in this journal accept the following conditions:
1. The authors retain the copyright and grant to the CAMbios MEDICAL-SCIENTIFIC JOURNAL HECAM the right of the first publication, with the work registered with the Creative Commons attribution license, which allows third parties to use the published material provided that they mention the authorship of the work and the first publication in this journal.
2. Authors can make other independent and additional contractual agreements for the non-exclusive distribution of the version of the article published in this journal (for example, include it in an institutional repository or publish it in a book) as long as it clearly indicates that the work was published. for the first time in the CAMbios MEDICAL-SCIENTIFIC JOURNAL HECAM.